Neoadjuvant Nivolumab Plus Ipilimumab Shows Trend Towards Long-Term Clinical Benefit versus Chemotherapy in Patients with Resectable NSCLC By Ogkologos - February 24, 2025 515 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 816 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR Survival Benefit of Enfortumab Vedotin and Pembrolizumab Compared with Chemotherapy in... March 11, 2024 Feasibility and Preliminary Efficacy Results of the Beat AML Study October 28, 2020 Can the New “Omics” on the Block Find Liver Cancer in... May 15, 2023 How to Discuss Your Goals of Care With Your Cancer Care... October 17, 2023 Load more HOT NEWS Two Years After Cancer Diagnosis, Swimmer Rikako Ikee Has Qualified For... Neoadjuvant Oxaliplatin-Fluoropyrimidine Chemotherapy Can Be Delivered Safely in Patients with Operable... Έγκριση νέας επικουρικής θεραπείας για τον θετικά πρώιμο καρκίνο του μαστού Fostering Black leadership in cancer research
